Literature DB >> 7846752

Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight.

M P Ducharme1, R L Slaughter, D J Edwards.   

Abstract

The effects of age, gender, and body weight on the pharmacokinetics of vancomycin were examined using data collected as part of routine therapeutic drug monitoring in patients. One thousand eighty-five sets of steady-state peak and trough serum concentrations obtained from 704 different patients were used to calculate elimination rate constant (k), volume of distribution (V), and clearance (Cl) using a one-compartment model. The median half-life of vancomycin was 6.5 h. Clearance was significantly correlated with creatinine clearance as estimated using the Cockcroft-Gault equation [Cl = 0.771 (Clcr) + 18.9; r = 0.63]. V averaged 0.69 L/kg ideal body weight (IBW) with increased values in females, patients over age 60, and obese patients. V ranged from 0.58 L/kg IBW in normal weight males under age 40 to 1.17 L/kg IBW in obese females over age 60. V was not different in underweight patients and those of normal weight (43.8 vs. 44.4 L). Regression analysis indicated that V was more predictable in women than in men and that vancomycin distributed into excess body weight (EBW) to a greater extent in women. However, the correlation coefficients from multiple regression analysis of V with IBW, EBW, and age did not exceed 0.60, and the high root mean square error values of 11-15 L suggest considerable variability in V is not accounted for by these factors alone. Despite these limitations, dosing of vancomycin may be improved by adjusting initial estimates of V for patient age, gender, and obesity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7846752     DOI: 10.1097/00007691-199410000-00013

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  40 in total

Review 1.  Vancomycin: a review of population pharmacokinetic analyses.

Authors:  Amélie Marsot; Audrey Boulamery; Bernard Bruguerolle; Nicolas Simon
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  Cystatin C and/or creatinine-based estimated glomerular filtration rate for prediction of vancomycin clearance in long-stay critically ill patients with persistent inflammation, immunosuppression and catabolism syndrome (PICS): a population pharmacokinetics analysis.

Authors:  Jingjing Huang; Xiaoli Wang; Chenxia Hao; Wanhua Yang; Weixia Zhang; Jialin Liu; Hongping Qu
Journal:  Intern Emerg Med       Date:  2021-03-16       Impact factor: 3.397

3.  Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery.

Authors:  Christine E Staatz; Colette Byrne; Alison H Thomson
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

4.  Evaluation of a New Vancomycin Dosing Protocol in Morbidly Obese Patients.

Authors:  Desiree E Kosmisky; Carrie L Griffiths; Megan A Templin; James Norton; Kelly E Martin
Journal:  Hosp Pharm       Date:  2015-10-14

Review 5.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

6.  Vancomycin vs teicoplanin in the treatment of Gram-positive infections: a pharmacoeconomic analysis in a Turkish University Hospital.

Authors:  Aylin Acar Sancar; Selen Yegenoglu; Robin de Vries; Maarten J Postma; Nimet Simsek; Petros Pechlivanoglou; Serhat Unal
Journal:  Pharm World Sci       Date:  2008-09-21

7.  Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies.

Authors:  Dolores Santos Buelga; María del Mar Fernandez de Gatta; Emma V Herrera; Alfonso Dominguez-Gil; María José García
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

8.  Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model.

Authors:  K Tateda; K Takashima; H Miyazaki; T Matsumoto; T Hatori; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

9.  Bayesian Estimation of Vancomycin Pharmacokinetics in Obese Children: Matched Case-Control Study.

Authors:  Jennifer Le; Edmund V Capparelli; Uzra Wahid; Yi Shuan S Wu; Gale L Romanowski; Tri M Tran; Austin Nguyen; John S Bradley
Journal:  Clin Ther       Date:  2015-05-29       Impact factor: 3.393

Review 10.  Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.

Authors:  Christopher Giuliano; Christopher Giulano; Krystal K Haase; Ronald Hall
Journal:  Expert Rev Anti Infect Ther       Date:  2010-01       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.